» Articles » PMID: 34526345

Searching for a Technology-driven Acute Rheumatic Fever Test: the START Study Protocol

Abstract

Introduction: The absence of a diagnostic test for acute rheumatic fever (ARF) is a major impediment in managing this serious childhood condition. ARF is an autoimmune condition triggered by infection with group A . It is the precursor to rheumatic heart disease (RHD), a leading cause of health inequity and premature mortality for Indigenous peoples of Australia, New Zealand and internationally. METHODS AND ANALYSIS: 'Searching for a Technology-Driven Acute Rheumatic Fever Test' (START) is a biomarker discovery study that aims to detect and test a biomarker signature that distinguishes ARF cases from non-ARF, and use systems biology and serology to better understand ARF pathogenesis. Eligible participants with ARF diagnosed by an expert clinical panel according to the 2015 Revised Jones Criteria, aged 5-30 years, will be recruited from three hospitals in Australia and New Zealand. Age, sex and ethnicity-matched individuals who are healthy or have non-ARF acute diagnoses or RHD, will be recruited as controls. In the discovery cohort, blood samples collected at baseline, and during convalescence in a subset, will be interrogated by comprehensive profiling to generate possible diagnostic biomarker signatures. A biomarker validation cohort will subsequently be used to test promising combinations of biomarkers. By defining the first biomarker signatures able to discriminate between ARF and other clinical conditions, the START study has the potential to transform the approach to ARF diagnosis and RHD prevention.

Ethics And Dissemination: The study has approval from the Northern Territory Department of Health and Menzies School of Health Research ethics committee and the New Zealand Health and Disability Ethics Committee. It will be conducted according to ethical standards for research involving Indigenous Australians and New Zealand Māori and Pacific Peoples. Indigenous investigators and governance groups will provide oversight of study processes and advise on cultural matters.

Citing Articles

The roles of immuno-modulator treatment and echocardiographic screening in rheumatic fever and rheumatic heart disease control: research from Aotearoa, New Zealand.

Wilson N, Anderson A, Baker M, Bennett J, Dennison A, McGregor R J R Soc N Z. 2024; 55(2):241-266.

PMID: 39677380 PMC: 11639061. DOI: 10.1080/03036758.2024.2306981.


An acute rheumatic fever immune signature comprising inflammatory markers, IgG3, and -specific antibodies.

Lorenz N, McGregor R, Whitcombe A, Sharma P, Ramiah C, Middleton F iScience. 2024; 27(8):110558.

PMID: 39184444 PMC: 11342286. DOI: 10.1016/j.isci.2024.110558.


Application of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenes.

Nakakana U, Serry-Bangura A, Edem B, Tessitore P, Di Cesare L, Moriel D Drugs R D. 2024; 24(1):1-12.

PMID: 38494581 PMC: 11035538. DOI: 10.1007/s40268-024-00452-y.


Outcomes of possible and probable rheumatic fever: A cohort study using northern Australian register data, 2013-2019.

Goddard L, Kaestli M, Makalic E, Ralph A PLOS Glob Public Health. 2024; 4(1):e0002064.

PMID: 38170692 PMC: 10763935. DOI: 10.1371/journal.pgph.0002064.


Research priorities for the secondary prevention and management of acute rheumatic fever and rheumatic heart disease: a National Heart, Lung, and Blood Institute workshop report.

Karthikeyan G, Watkins D, Bukhman G, Cunningham M, Haller J, Masterson M BMJ Glob Health. 2023; 8(Suppl 9).

PMID: 37914183 PMC: 10618973. DOI: 10.1136/bmjgh-2023-012468.


References
1.
Pertea M, Kim D, Pertea G, Leek J, Salzberg S . Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc. 2016; 11(9):1650-67. PMC: 5032908. DOI: 10.1038/nprot.2016.095. View

2.
Sjoberg R, Mattsson C, Andersson E, Hellstrom C, Uhlen M, Schwenk J . Exploration of high-density protein microarrays for antibody validation and autoimmunity profiling. N Biotechnol. 2015; 33(5 Pt A):582-92. DOI: 10.1016/j.nbt.2015.09.002. View

3.
Wilms I, Croux C . Robust sparse canonical correlation analysis. BMC Syst Biol. 2016; 10(1):72. PMC: 4982144. DOI: 10.1186/s12918-016-0317-9. View

4.
Wyber R, Noonan K, Halkon C, Enkel S, Cannon J, Haynes E . Ending rheumatic heart disease in Australia: the evidence for a new approach. Med J Aust. 2020; 213 Suppl 10:S3-S31. DOI: 10.5694/mja2.50853. View

5.
Amenyogbe N, Dimitriu P, Smolen K, Brown E, Shannon C, Tebbutt S . Biogeography of the Relationship between the Child Gut Microbiome and Innate Immune System. mBio. 2021; 12(1). PMC: 7845628. DOI: 10.1128/mBio.03079-20. View